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OBJECTIVES: To evaluate the reactivity of indirect immunofluorescence using rat bladder epithelium as a substrate
in patients with pemphigus foliaceus and pemphigus vulgaris from the Department of Dermatology, University of
Sa˜o Paulo Medical School, Brazil.
METHODS: Thirty-two patients (8 male and 24 female) from the Department of Dermatology, University of Sa˜o
Paulo Medical School, were selected. Three had mucosal pemphigus vulgaris, 20 had mucocutaneous pemphigus
vulgaris, and 9 had pemphigus foliaceus. Patients’ sera were tested by indirect immunofluorescence performed on
human foreskin and rat bladder epithelium and by ELISA assays utilizing baculovirus-expressed recombinant
desmoglein 3 and desmoglein 1.
RESULTS: No patients with mucosal pemphigus vulgaris, 5 of 20 patients with mucocutaneous pemphigus vulgaris
(25%) and 4 of 9 patients with pemphigus foliaceus (44%) had positive indirect immunofluorescence using rat
bladder epithelium as a substrate.
CONCLUSION: Indirect immunofluorescence using rat bladder epithelium as a substrate is recommended whenever
a diagnosis of paraneoplastic pemphigus is considered. The identification of a subset of pemphigus foliaceus and
pemphigus vulgaris patients that recognizes desmoplakins by this laboratory tool is critical to avoid the misdiagnosis
of paraneoplastic pemphigus.
KEYWORDS: Pemphigus vulgaris; Paraneoplastic pemphigus; Indirect immunofluorescence; Rat bladder epithelium;
Pemphigus foliaceus.
Ortolan DG, Souza DPG, Aoki V, Santi CG, Gabbi TVB, Ichimura LMF, et al. Analysis of the reactivity of indirect immunofluorescence in patients with
pemphigus foliaceus and pemphigus vulgaris using rat bladder epithelium as a substrate. Clinics. 2011;66(12):2019-2023.
Received for publication on May 1, 2011; First review completed on May 26, 2011; Accepted for publication on August 18, 2011
E-mail: cwmaruta@terra.com.br
Tel.: 55 11 26618036
INTRODUCTION
Desmoplakin I (DP I) and desmoplakin II (DP II) are
constitutive desmosomal plaque proteins that provide a link
between the desmosomal cadherin and the intermediate
filament cytoskeleton, thereby contributing to the functional
integrity of the desmosome-keratin filament complex.1 DP
autoantibodies are present in paraneoplastic pemphigus
(PNP) as a component of a complex humoral immune
reaction2 and were once considered to be a sensitive and
specific feature in the diagnosis of PNP.3 However, these
autoantibodies have also been found in other diseases,
including pemphigus foliaceus (PF), pemphigus vulgaris
(PV), bullous pemphigoid (BP), and erythema multiforme
major.4-12 A possible mechanism for the development of
autoantibodies to DP in those dermatoses is explained by
the epitope-spreading phenomenon.5,6 This phenomenon
includes an initial autoimmune response against a specific
antigen that may lead to the recognition of other antigens
that are not necessarily related by homology but are
physically linked or share proximal locations.13
The presence of anti-DP antibodies in IgG-mediated
pemphigus does not seem to characterize a particular
subgroup,7 and it is unlikely that these antibodies could be
solely responsible for acantholysis. It is possible that anti-DP
antibodies could potentiate the disruption in cell-cell adhe-
sion originally initiated by anti-desmoglein antibodies.6
The urinary bladder epithelium has desmosomes that
contain DP I and/or DP II but do not express PF or PV
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antigens.14 Therefore, the reactivity of indirect immuno-
fluorescence using rat bladder epithelium (IIF-RBE) as a
substrate in patients with PF or PV suggests the presence of
anti-DP autoantibodies.
OBJECTIVES
The aim of this study was to analyze the reactivity of IIF-
RBE in patients with PF and PV from the Department of
Dermatology, University of Sa˜o Paulo Medical School to
evaluate whether this diagnostic tool could lead to a
misdiagnosis of PNP for PF and PV patients.
MATERIALS AND METHODS
Upon approval by the Ethics Committee, 32 patients (8
male and 24 female, with a mean age of 45 years) followed up
by the Department of Dermatology, University of Sa˜o Paulo
Medical School between 1994 and 2009 were selected for the
study. Three of 32 patients had mucosal pemphigus vulgaris
(MPV), 20 had mucocutaneous pemphigus vulgaris (MCPV),
and 9 had pemphigus foliaceus (PF). All diagnoses were
confirmed by clinical, histopathological, and direct immuno-
fluorescence evaluations. No patients were diagnosed with
PNP until the completion of this study. The disease activity
was classified according to the criteria adapted from the
consensus statement on definitions of the disease, end points
and the therapeutic response for pemphigus (Table 1).15
Patients’ sera were tested by indirect immunofluores-
cence and an enzyme-linked immunosorbent assay (ELISA).
IIF analysis of the patients’ sera was performed on human
foreskin and rat bladder epithelium. ELISA tests utilized
baculovirus-expressed recombinant desmoglein 3 (Dsg3)
and desmoglein 1 (Dsg1).
1. Indirect immunofluorescence using human foreskin
(IIF-HFS) or rat bladder epithelium (IIF-RBE) as a substrate:
Four micrometer cryostat sections of HFS and RBE were
incubated for 60 minutes with sera dilutions starting at
1520. The slides were washed in Tris-buffered saline (TBS)
twice (20 minutes each) and then covered with fluorescein
isothiocyanate-conjugated (FITC) goat anti-human IgG at a
dilution of 1530 (Sigma, USA) for 30 minutes. After two
additional 20-minute washes (TBS), the slides were
mounted in buffered glycerol and examined under an
epiluminescent microscope (Zeiss, Germany).
1. ELISA
Sera samples (15100 dilution) were added to microwell
plates coated with baculovirus-expressed desmogleins for 60
minutes. After washing, horseradish peroxidase-conjugated
IgG was added and allowed to incubate for 60 minutes.
Following another wash, the peroxidase substrate was added
and allowed to incubate for an additional 30 minutes. Then, a
1.0-N sulfuric acid solution was added to each well to
terminate the enzyme reaction and stabilize the color
development. The absorbance was measured at 450 nm by
an ELISA plate reader (MBL, Japan). A single PF serum
sample and a single PV serum sample were selected as
positive control serum samples for the Dsg1 and Dsg3
ELISAs, respectively. The index was calculated as follows:
index = (optical density (OD) of the tested serum - OD of the
negative control)/(OD of the positive control serum - OD of
the negative control)6100. The interpretation of results was
conducted according to the following parameters.
RESULTS
Mucosal pemphigus vulgaris (MPV)
All MPV patients (n = 3) were in partial remission on
therapy, and the mean follow-up time was 4.6 months. All
patients had negative IIF-RBE and positive IIF-HFS, with
titers ranging from 1540 to 15320 (mean titer of 15160). All
had positive ELISA results for Dsg3, and 1 patient also had a
positive ELISA result for Dsg1.
Mucocutaneous pemphigus vulgaris (MCPV)
Seventeen of 20 MCPV patients were classified as in
partial remission on therapy, and 4 (23%) had positive IIF-
RBE. Three of 20 MCPV patients were classified as in partial
remission on minimal therapy, and 1 (33%) had positive IIF-
RBE. Therefore, 5 of 20 (25%) PV sera showed reactivity in
IIF-RBE, with titers ranging from 1540 to 15160 (mean titer
of 1580) (Figure 1).
Positive IIF-HFS was in 18 of 20 MCPV sera, with titers
ranging from 1580 to 155,120 (mean titer of 151,280). The 2
PV patients with negative IIF-HFS were in partial remission
on therapy.
The mean IIF-HFS titer among patients with MCPV in
partial remission on therapy was 151,280 (mean titer of
151,280 among patients with positive IIF-RBE and 151,280
among patients with negative IIF-RBE). The mean titer of
Table 1 - Classification of disease activity.
Complete remission Off therapy Absence of new or established lesions while the patient is off all systemic therapy for at least 2
months
On therapy
Partial remission Off therapy Presence of transient new lesions that heal within 1 week without treatment and while the
patient is off all systemic therapy for at least 2 months
On therapy The presence of transient new lesions that heal within 1 week while the patient is receiving
systemic therapy
On minimal therapy The presence of transient new lesions that heal within 1 week while the patient is receiving
minimal therapy, including topical steroids
Relapse/Flare Appearance of at least three lesions/month that do not heal spontaneously within 1 week, or by
the extension of established lesions, in a patient who has achieved disease control
1. Dsg1
Less than 14 Negative
14 to 20 Indeterminate
Greater than 20 Positive
1. Dsg3
Less than 9 Negative
9 to 20 Indeterminate
Greater than 20 Positive
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IIF-HFS among the MCPV patients in partial remission on
minimal therapy was 151,280 (mean titer of 152,560 among
patients with positive IIF-RBE and 15160 among patients
with negative IIF-RBE).
Seventeen of 20 MCPV patients had positive ELISA
results for Dsg3, and 10 were anti-Dsg1 positive.
The mean follow-up time of the MCPV patients was five
years. MCPV patients in partial remission on therapy had a
mean follow-up of five years (three years among patients
with positive IIF-RBE and six years among patients with
negative IIF-RBE). MCPV patients in partial remission on
minimal therapy had a mean follow-up of four years (four
years among patients with positive IIF-RBE and three years
among patients with negative IIF-RBE).
The overall reactivity of IIF-RBE in all 23 PV patients was
22% (5/23).
Pemphigus foliaceus (PF)
Interestingly, four out of nine PF patients had a positive
IIF-RBE with titers ranging from 1520 to 1580 (mean titer of
1540). All were in partial remission. The overall reactivity of
IIF-RBE in all nine PF patients was 44% (4/9) (Figure 2).
Five of nine PF patients were classified as in partial
remission on therapy, and two (40%) had positive IIF-RBE.
Four of nine PF patients were classified as in remission on
minimal therapy, and two (50%) had positive IIF-RBE. All
nine PF sera showed positive results for IIF-HFS, with titers
ranging from 1580 to 155,120 (mean titer of 151,280).
All nine PF sera showed negative results for Dsg3 ELISA,
and one showed negative Dsg1 ELISA results. This patient
was in partial remission on minimal therapy.
The mean IIF-HFS titer among patients with PF in partial
remission on therapy was 151,280 (mean titer of 152,560
among patients with positive IIF-RBE and 151,280 among
patients with negative IIF-RBE). The mean IIF-HFS titer
among patients with PF in partial remission on minimal
therapy was 151,280 (mean titer of 151,280 among patients
with positive IIF-RBE and negative IIF-RBE).
PF patients with positive IIF-RBE had a long-term disease
(4-15 years). The mean follow-up of the PF patients was five
years. Patients with PF in partial remission on therapy had a
mean follow-up of six years (ten years among patients with
positive IIF-RBE and three years among patients with
negative IIF-RBE). Patients with PF in partial remission on
minimal therapy had a mean follow-up of six years (four
years among patients with positive IIF-RBE and eight years
among patients with negative IIF-RBE).
The demographic data from the patients are shown in
Table 2.
DISCUSSION
The use of RBE as a substrate for IIF in PNP started in
1990 with Anhalt et al.16 The specificity of the RBE substrate
for PNP was reported to be high, varying from 83% to
95%.3,14,17 However, Cozzani et al.7 found 21% positive IIF-
RBE in patients with PV, which is in accord with our data
(22% in PV patients). These authors suggested a role for
anti-DP in determining disease severity.6,7 In our study, all
PV patients with positive IIF-RBE belonged to the mucocu-
Figure 1 - (A) Clinical aspects of the lesions of a PV patient and (B)
the results of direct immunofluorescence demonstrating inter-
cellular IgG at the basal layers of the epidermis (6400); (C)
indirect immunofluorescence using human foreskin as a sub-
strate showing intercellular intraepidermal IgG deposits (6400);
and (D) indirect immunofluorescence using rat bladder epithe-
lium as a substrate demonstrating intercellular intraepithelial
IgG deposits (6400).
Figure 2 - (A) Clinical aspects of the lesions of a PV patient and (B)
the results of direct immunofluorescence demonstrating inter-
cellular intraepidermal IgG deposits (6400); (C) indirect immuno-
fluorescence using human foreskin as a substrate showing
intercellular intraepidermal IgG deposits (6400); and (D) indirect
immunofluorescence using rat bladder epithelium as a substrate
demonstrating intercellular intraepithelial IgG deposits (6400).
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taneous variant, and this observation supports that sugges-
tion; however, those patients were in partial remission. In
our study, there was not a clear correlation between the IIF-
RBE results and disease activity. Furthermore, the results of
IIF-HFS and the follow-up time did not correlate with the
reactivity of IIF-RBE.
Anti-desmoglein 1 and/or 3 autoantibodies were detected
in all patients except for one who had PF in clinical
remission on minimal therapy. The presence of these
autoantibodies reinforced the diagnosis of PF or PV. The
sensitivity and specificity of ELISA with recombinant Dsg1
and 3 is reported to be approximately 95-98%.18
Anti-DP antibodies have previously been described in
one PF patient,4 which is in contrast to our IIF-RBE results
showing reactivity in 4 of 9 PF patients (44%). All PF
patients had a long-term follow-up (4-15 years).
The long-term follow-up of our positive IIF-RBE patients
(three years for MCPV and six years for PF) may indicate
that these patients will not develop PNP.
A possible explanation for the presence of anti-DP antibodies
in PF and PV is the epitope spreading phenomenon. However,
it is unlikely that anti-DP antibodies in our PF and PV patients
played a role in the loss of keratinocyte adhesion, leading to
acantholysis and blister formation. Moreover, the possible
presence of anti-DP autoantibodies in these patients could be
explained by long-term chronic autoimmune disease.
IIF-RBE is a relevant tool when considering patients with
PNP. The anti-desmoplakin response of IIF-RBE is not a
routine technique employed to investigate PF or PV patients
and should only be performed in patients with suspected
PNP. The identification of a subset of PF and PV patients with
positive IIF-RBE is relevant to avoid a misdiagnosis of PNP in
doubtful cases. Therefore, the correlation of clinical features,
histopathology, direct immunofluorescence, and indirect
immunofluorescence is necessary to achieve correct diagnoses.
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